China’s drug regulator clears wave of home-grown innovative medicines amid biotech boom

China’s National Medical Products Administration (NMPA) approved 19 innovative drugs in 2024, with 15 developed by domestic companies, highlighting the country’s biotech growth. Notable approvals include sonrotoclax by BeOne for treating adult blood cancers, as the regulator streamlines its approval process.